Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
Company profile
Ticker
CLDI, CLDI-WT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
First Light Acquisition Group, Inc.
SEC CIK
Corporate docs
IRS number
862967193
CLDI stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
19 Apr 24
8-K
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
19 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Apr 24
424B4
Prospectus supplement with pricing info
17 Apr 24
EFFECT
Notice of effectiveness
17 Apr 24
S-1/A
IPO registration (amended)
15 Apr 24
S-1/A
IPO registration (amended)
8 Apr 24
S-1/A
IPO registration (amended)
2 Apr 24
8-K
Entry into a Material Definitive Agreement
1 Apr 24
S-1/A
IPO registration (amended)
29 Mar 24
Latest ownership filings
4
James A Schoeneck
22 Apr 24
3
David LaPre
12 Mar 24
SC 13G/A
683 Capital Management, LLC
14 Feb 24
SC 13G/A
First Light Acquisition Group, LLC
14 Feb 24
SC 13G/A
First Trust Capital Management L.P.
12 Feb 24
SC 13G/A
Woodline Partners LP
12 Feb 24
SC 13G/A
SPRING CREEK CAPITAL LLC
9 Feb 24
SC 13G/A
Polar Asset Management Partners Inc.
9 Feb 24
4
Alfonso G Zulueta
4 Jan 24
4
Alan R. Stewart
4 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.37 mm | 10.37 mm | 10.37 mm | 10.37 mm | 10.37 mm | 10.37 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.41 mm | 1.78 mm | 4.51 mm | 2.14 mm |
Cash used (since last report) | n/a | n/a | 16.43 mm | 12.13 mm | 30.75 mm | 14.60 mm |
Cash remaining | n/a | n/a | -6.06 mm | -1.76 mm | -20.38 mm | -4.24 mm |
Runway (months of cash) | n/a | n/a | -2.5 | -1.0 | -4.5 | -2.0 |
Institutional ownership, Q3 2023
58.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 10 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.17 bn |
Total shares | 20.82 mm |
Total puts | 0.00 |
Total calls | 187.09 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Allan Camaisa | 6.10 mm | $0.00 |
Jackson Investment | 2.88 mm | $0.00 |
First Light Acquisition | 2.58 mm | $0.00 |
Polar Asset Management Partners | 2.17 mm | $508.80 mm |
Scott Leftwich | 1.76 mm | $0.00 |
Funicular Funds | 716.32 k | $6.58 mm |
Finepoint Capital | 655.20 k | $144.14 mm |
Shaolin Capital Management | 650.00 k | $143.00 k |
Meteora Capital | 612.86 k | $5.63 mm |
683 Capital Management | 600.00 k | $132.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Schoeneck James A | Common Stock | Grant | Acquire A | Yes | No | 0.4 | 375,000 | 150.00 k | 415,887 |
18 Apr 24 | Schoeneck James A | Series C Unit | Grant | Acquire A | Yes | No | 0.6 | 375,000 | 225.00 k | 375,000 |
18 Apr 24 | Schoeneck James A | Series B Unit | Grant | Acquire A | Yes | No | 0.6 | 375,000 | 225.00 k | 375,000 |
18 Apr 24 | Schoeneck James A | Common Stock | Grant | Acquire A | Yes | No | 0.6 | 375,000 | 225.00 k | 375,000 |
21 Dec 23 | Thomas A. Vecchiolla | Common Stock | Grant | Acquire A | No | No | 1.8 | 7,709 | 13.88 k | 365,105 |
21 Dec 23 | Allan Camaisa | NQSO Common stock | Grant | Acquire A | No | No | 1.8 | 100,000 | 180.00 k | 100,000 |
21 Dec 23 | Scott Leftwich | Common Stock | Grant | Acquire A | No | No | 1.8 | 8,958 | 16.12 k | 469,903 |
21 Dec 23 | Scott Leftwich | NQSO Common stock | Grant | Acquire A | No | No | 1.8 | 70,249 | 126.45 k | 70,249 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
19 Apr 24
S&P 500 Edges Lower; PacBio Shares Plunge
16 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
16 Apr 24
Gold Moves Higher; Morgan Stanley Earnings Top Views
16 Apr 24
Press releases
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
19 Apr 24
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
16 Apr 24
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024
9 Apr 24
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
11 Mar 24
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
12 Feb 24